Activating Your Body'sNatural Cancer Killers

Yes — completely free and no obligation. It's an educational session to help you understand integrative immunotherapy options. You're welcome to invite a spouse, family member, or caregiver.

Register anyway. Everyone who signs up receives a replay link by email, so you can watch when it's convenient. Attending live is best, though — that's your chance to ask Dr. Sosa questions directly.

After registering you'll receive a private Zoom link by email, plus reminders before the event. Just click the link at 11:00 AM Mexico City time on Thursday, June 11 from any phone, tablet, or computer.

The webinar explains who the Integrative Oncology Program is designed for and how candidacy is evaluated. Dr. Sosa personally reviews each individual case — the session is the perfect first step to understand your options.

NK cells are innate immune lymphocytes — the body's rapid-response "first responders." Unlike T cells, they don't need to be pre-trained against a specific target. They read two opposing signals on every cell: inhibitory signals from "self" markers called MHC class I, and activating signals from stress molecules (like MICA/MICB) that appear on damaged or transformed cells. Many tumor cells shed their MHC-I to hide from T cells — but that "missing self" is exactly what flips NK cells on. Once engaged, an NK cell releases perforin and granzymes that open the target's membrane and trigger apoptosis (programmed cell death). In cell therapy, NK cells are expanded outside the body and reinfused to increase their numbers and activity. (Investigational for solid tumors.)

Immune cells carry built-in "off switches" (checkpoints) that normally stop them from attacking healthy tissue. The PD-1 receptor on a T cell is one of these. Tumors exploit it by displaying the matching ligand, PD-L1 — pressing the brake so the immune cell powers down. OPDIVO® (nivolumab) is an FDA-approved anti-PD-1 antibody that physically caps PD-1 so PD-L1 can no longer engage it. The brake is released and the immune cell stays active against the tumor. Pairing checkpoint blockade with cell therapies (NK, LAK, dendritic-cell) is an area of active investigation.

The Cytotron is a non-invasive device based on Rotational Field Quantum Magnetic Resonance (RFQMR). It delivers focused, modulated radiofrequency energy intended to influence the cell's transmembrane potential and nudge dysregulated cells back toward their natural apoptosis (programmed-cell-death) pathways. It received an FDA Breakthrough Device Designation in 2019 for breast, liver, and pancreatic cancers. Important: a Breakthrough Device Designation is an expedited-review status for an investigational device — it is not FDA approval or clearance, and the published clinical evidence is early-stage and largely uncontrolled.

The process is a form of adoptive cell therapy. A starting population of NK cells is obtained — either from the patient (autologous) or a screened donor (allogeneic) — typically via a blood draw or leukapheresis. In a certified lab the cells are cultured ex vivo with cytokines such as interleukin-2 (IL-2) and interleukin-15 (IL-15), often alongside engineered feeder/antigen-presenting cells, which drives them to multiply many-fold and ramp up their cytotoxic machinery. After purity, viability, and sterility checks, the activated NK cells are reinfused intravenously so a larger, more active population is circulating. Because NK cells are short-lived, protocols often use repeated infusions. (Adoptive NK cell therapy is investigational for solid tumors and is not FDA-approved for these uses.)

They target different arms of the immune system. NK (Natural Killer) therapy amplifies innate \"first-responder\" cells that kill stressed or MHC-deficient cells without prior training. LAK (Lymphokine-Activated Killer) therapy takes a mixed population of lymphocytes (NK and T cells) and super-activates them with high-dose IL-2, producing broad cytotoxic activity. Dendritic-cell therapy works upstream and differently: dendritic cells are the immune system's \"teachers\" — they are loaded with tumor antigens and reinfused to train the patient's own T cells to recognize the cancer, more like a personalized therapeutic vaccine. An integrative protocol may combine these so innate killing, broad cytotoxicity, and antigen-specific training reinforce one another. (All three are investigational for these uses and not FDA-approved.)

Every living cell holds a small voltage across its membrane — the transmembrane potential — and rapidly dividing cells tend to sit in a more depolarized (less negative) state than mature, quiescent tissue. Rotational Field Quantum Magnetic Resonance (RFQMR) delivers focused, low-energy radiofrequency pulses tuned to a narrow resonance window, with the stated aim of perturbing that transmembrane potential in dysregulated cells and nudging them back toward their natural apoptosis (orderly programmed-cell-death) pathway rather than uncontrolled growth — while aiming to leave normal, slower-cycling tissue largely undisturbed. Important honesty note: this is the proposed mechanism, not a proven one. The Cytotron holds an FDA Breakthrough Device Designation (an expedited-review status for an investigational device — not approval or clearance), and the published human evidence is early-stage and largely uncontrolled.

They are two very different ways a cell can die. Apoptosis is programmed, orderly \"cellular self-destruct\": the cell shrinks, fragments its DNA, packages itself into tidy membrane-bound bodies, and is cleared quietly by the immune system — with little surrounding inflammation. Necrosis is uncontrolled cell rupture that spills the cell's contents and triggers inflammation and collateral damage. Many cancers survive partly by evading apoptosis. The therapies discussed in this webinar — from NK-cell killing (via perforin/granzyme signaling) to the Cytotron's proposed effect on transmembrane potential — are oriented toward restoring the apoptotic route, the body's own clean, controlled mechanism for removing abnormal cells. This is educational background, not a claim of guaranteed effect.

No. The webinar is educational and informational only. It is not a substitute for personalized medical advice, diagnosis, or treatment from a qualified provider.